최신약물정보 (FDA 승인 약물 2014.7-2014.9)

Jublia (efinaconazole) 10% topical gel; Valeant Pharmaceuticals; For the treatment of onychomycosis of the toenails, Approved June 2014
Kerydin (tavaborole); Anacor; For the treatment of onychomycosis of the toenails, Approved July 2014
Keytruda (pembrolizumab); Merck; For the treatment of unresectable or metastatic melanoma, Approved September 2014
Orbactiv (oritavancin); The Medicines Company; For the treatment of acute bacterial skin and skin structure infections, Approved August 2014
Otezla (apremilast); Celgene; For the treatment of moderate to severe plaque psoriasis, Approved September 2014
Sivextro (tedizolid phosphate) ; Cubist Pharmaceuticals; For the treatment of acute bacterial skin and skin structure infections, Approved June 2014
Afrezza (insulin human) Inhalation Powder; Mannkind; For the treatment of diabetes mellitus, Approved June 2014
Jardiance (empagliflozin) ; Boehringer Ingelheim; For the treatment of type II diabetes, Approved August 2014
Trulicity (dulaglutide); Eli Lilly; To improve glycemic control in type II diabetics, Approved September 2014
Vogelxo (testosterone) gel; Upsher-Smith; For males with a deficiency or absence of endogenous testosterone, Approved June 2014
Arnuity Ellipta (fluticasone furoate inhalation powder); GlaxoSmithKline; For the treatment of asthma, Approved August 2014
Belsomra (suvorexant); Merck; For the treatment of insomnia, Approved August 2014
Bunavail (buprenorphine and naloxone); BioDelivery Sciences; For the maintenance treatment of opioid dependence, Approved June 2014
Contrave (naltrexone HCl and bupropion HCl) ; Takeda Pharmaceuticals U.S.A.; For chronic
Plegridy (peginterferon beta-1a); Biogen IDEC.; For the treatment of relapsing multiple sclerosis, Approved August 2014
Targiniq ER (oxycodone hydrochloride + naloxone hydrochloride) extended-release tablets; Purdue Pharma; For the management of severe chronic pain, Approved July 2014
Trulicity (dulaglutide); Eli Lilly; To improve glycemic control in type II diabetics, Approved September 2014
Movantik (naloxegol); AstraZeneca; For the treatment of opiod-induced constipation in adults with chronic non-cancer pain, Approved September 2014
Cerdelga (eliglustat); Genzyme; For the treatment of certain adult patients with Gaucher Hematology
Beleodaq (belinostat); Spectrum Pharmaceuticals; For the treatment of relapsed or refractory peripheral T-cell lymphoma, Approved July 2014
Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein] ; Biogen IDEC.; For the treatment of hemophillia A, Approved June 2014
Ruconest (C1 esterase inhibitor [recombinant]); Pharming Group; For the treatment of hereditary angioedema, Approved July 2014
Zydelig (idelalisib); Gilead; For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma, Approved July 2014
HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]; Baxter; For the treatment of Primary Immunodeficiency, Approved September 2014
Triumeq (abacavir, dolutegravir, and lamivudine); ViiV HealthCare; For the treatment of HIV-1, Approved August 2014
Jublia (efinaconazole) 10% topical gel; Valeant Pharmaceuticals; For the treatment of onychomycosis of the toenails, Approved June 2014
Kerydin (tavaborole); Anacor; For the treatment of onychomycosis of the toenails, Approved July 2014
Orbactiv (oritavancin); The Medicines Company; For the treatment of acute bacterial skin and skin structure infections, Approved August 2014
Sivextro (tedizolid phosphate) ; Cubist Pharmaceuticals; For the treatment of acute bacterial skin and skin structure infections, Approved June 2014
Triumeq (abacavir, dolutegravir, and lamivudine); ViiV HealthCare; For the treatment of HIV-1, Approved August 2014
Cerdelga (eliglustat); Genzyme; For the treatment of certain adult patients with Gaucher disease type 1, Approved August 2014
Ferric citrate; Keryx Biopharma; For the treatment of hyperphosphatemia in patients with chronic kidney disease, Approved September 2014
Belsomra (suvorexant); Merck; For the treatment of insomnia, Approved August 2014
Movantik (naloxegol); AstraZeneca; For the treatment of opiod-induced constipation in adults with chronic non-cancer pain, Approved September 2014
Contrave (naltrexone HCl and bupropion HCl) ; Takeda Pharmaceuticals U.S.A.; For chronic weight management , Approved September 2014
Jardiance (empagliflozin) ; Boehringer Ingelheim; For the treatment of type II diabetes, Approved August 2014
Keytruda (pembrolizumab); Merck; For the treatment of unresectable or metastatic melanoma, Approved September 2014
Zydelig (idelalisib); Gilead; For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma, Approved July 2014
Omidria (phenylephrine and ketorolac injection); Omeros; For use during eye surgery to prevent intraoperative miosis and reduce post-operative pain, Approved June 2014
Arnuity Ellipta (fluticasone furoate inhalation powder); GlaxoSmithKline; For the treatment of asthma, Approved August 2014
Striverdi Respimat (olodaterol); Boehringer Ingelheim; For the treatment of chronic obstructive pulmonary disease , Approved July 2014

• 
• 

•   일본뇌염 세포배양백신 국가예방접종 도입   2015-03-04 12:57
•   “디클로페낙”함유 의약품(정제)의 일일 최대권장량 감량 권고   2014-11-15 11:33
•   최신약물정보 (FDA 승인 약물 2014.7-2014.9)    
•   최신약물정보 (FDA 승인 약물 2014.3-2014.6)   2014-07-03 15:03
•   레닌-안지오텐신계(RAS) 작용 의약품 관련 안전성 서한   2014-07-03 13:32